

Press Release 17 November 2022 14:00:00 CET

# Qlucore software used in new project to prevent cardiovascular diseases

# - Receives SEK 1.5 million to provide patients with better treatment

Nasdaq First North-listed Qlucore, a leading provider of visualization-based software for research and companion diagnostics, will play an important role as one of five key partners in the OmegaPerMed project. The project aims to optimize treatment with omega-3 to prevent cardiovascular diseases (CVD).

Cardiovascular diseases, such as heart attack, stroke and angina, are the most common causes of death in populations, and therefore prevention is vital.

"This project is the starting point for the development of our solutions in a second major disease area – cardiovascular diseases. It complements our ongoing work in cancer areas such as leukemia and thus broadens the potential health benefit areas, says Carl-Johan Ivarsson, CEO of Qlucore.

In clinical trials, the project will try to detect interactions between genes, exposure to polyunsaturated fatty acid (PUFA), CVD risk and lipidomic markers against beneficial CVD effects of omega-3 PUFA. I This means that if successful, patients can be divided into subgroups in order to receive a more individualized treatment.

"We are providing the project with a machine learning software environment. We will develop artificial intelligence (AI) methods to build CVD-specific classification models that are easy to use for healthcare professionals with patient-friendly visualizations", says Carl-Johan Ivarsson. He continues:

"We are especially proud that our bioinformatician, Caroline Brorsson, is one of the project research leaders."

The project results for the optimization of omega-3 treatment may provide the first individually adapted treatment to be widely implemented under international guidelines for CVD treatment, potentially benefiting a large patient population in Europe and worldwide.

The project will be co ordinated by Professor Magnus Bäck at INSERM, France.

**Qlucore** Sweden Ideon Science Park, Scheelevägen 17, 223 70 Lund. **Qlucore** USA 900 Third Avenue, 29th Floor, New York, NY 10022.



#### **Certified Advisor**

FNCA Sweden AB Web: www.fnca.se

#### Contacts

Press contact: Chaz Brooks / Alison Scarrott / Mandy Brooks Brookscomm Phone: +44 (0) 1483 537 890 Email: <u>alison@brookscomm.com</u>

Qlucore contact: Carl-Johan Ivarsson, CEO Phone: +46 (0) 46 286 31 14 Email: carl-johan.ivarsson@qlucore.com

# About Qlucore

Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore's mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a Do-It-Yourself bioinformatics software for research in the life science, plant- and biotech industries, as well as academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market. www.qlucore.com

# Image Attachments

PM Cardio 221117 Carl Johan Ivarsson Qlucore Caroline Brorsson Qlucore

**Qlucore** Sweden Ideon Science Park, Scheelevägen 17, 223 70 Lund. **Qlucore** USA 900 Third Avenue, 29th Floor, New York, NY 10022.



# Attachments

Qlucore software used in new project to prevent cardiovascular diseases

**Qlucore** Sweden Ideon Science Park, Scheelevägen 17, 223 70 Lund. **Qlucore** USA 900 Third Avenue, 29th Floor, New York, NY 10022.